BRUCE ALFRED DOLL
Dentist in Wexford, PA
License number
Pennsylvania DS025154L
Category
Dentistry
Type
Dentist
Address
Address
Wexford, PA 15090
Personal information
See more information about BRUCE ALFRED DOLL at radaris.comName
Address
Phone
10325 Ridgecrest Pt, Wexford, PA 15090
139 Edward Rd, York, PA 17403
6272 Kaylor Ct, Slatington, PA 18080
119 Timberline, Lehigh Valley, PA 18002
10325 Ridgecrest Pt, Wexford, PA 15090
Professional information
See more information about BRUCE ALFRED DOLL at trustoria.com
Dr. Bruce Doll, Wexford PA - DDS (Doctor of Dental Surgery)
Dr. Bruce Doll, Wexford PA - DDS (Doctor of Dental Surgery)
Specialties:
Periodontics
Address:
10325 Ridgecrest Pt, Wexford 15090
(724) 934-8403 (Phone)
(724) 934-8403 (Phone)
Languages:
English
Compositions And Devices Comprising Or Encoding The Run X2 Protein And Method Of Use
Compositions And Devices Comprising Or Encoding The Run X2 Protein And Method Of Use
US Patent:
2003023, Dec 25, 2003
Filed:
May 13, 2003
Appl. No.:
10/437171
Inventors:
Bruce Doll - Wexford PA, US
Huihua Fu - Pittsburgh PA, US
Jeffrey Hollinger - Gibsonia PA, US
Charles Sfeir - Pittsburgh PA, US
Huihua Fu - Pittsburgh PA, US
Jeffrey Hollinger - Gibsonia PA, US
Charles Sfeir - Pittsburgh PA, US
International Classification:
A61K048/00, A61K038/17
US Classification:
424/093210, 424/426000, 514/012000, 514/044000
Abstract:
A pharmaceutical composition comprising in combination the Runx2 protein, a polynucleotide encoding the Runx2 protein, or a cell that has been transformed with a polynucleotide encoding Runx2 protein, in a pharmaceutically acceptable carrier, the carrier comprising a bio-compatible, biodegradable polymeric matrix. Another aspect of the present invention includes a device comprising the above-described pharmaceutical composition in combination with a sterile and substantially antigen-free, pre-shaped allograft or xenograft bone implant. Also contemplated herein is a method for repairing a bone defect comprising administering to a mammalian patient at the site in need of treatment a pharmaceutical composition, comprising in combination the Runx2 protein, a polynucleotide encoding the Runx2 protein, or a cell that has been transformed with a polynucleotide encoding Runx2 protein, in a pharmaceutically acceptable carrier wherein the carrier is a bio-compatible, biodegradable polymeric matrix.
Biodegradable Polyurethanes And Use Thereof
Biodegradable Polyurethanes And Use Thereof
US Patent:
2005001, Jan 20, 2005
Filed:
Jan 16, 2004
Appl. No.:
10/759904
Inventors:
Eric Beckman - Aspinwall PA, US
Jeffrey Hollinger - Gibsonia PA, US
Bruce Doll - Wexford PA, US
Scott Guelcher - Weirton WV, US
Jianying Zhang - Pittsburgh PA, US
Jeffrey Hollinger - Gibsonia PA, US
Bruce Doll - Wexford PA, US
Scott Guelcher - Weirton WV, US
Jianying Zhang - Pittsburgh PA, US
International Classification:
A61K031/785, C08G063/48, C08G063/91
US Classification:
424078270, 525054100, 525054200
Abstract:
A biodegradable and biocompatible polyurethane composition synthesized by reacting isocyanate groups of at least one multifunctional isocyanate compound with at least one bioactive agent having at least one reactive group —X which is a hydroxyl group (—OH) or an amine group (—NH). The polyurethane composition is biodegradable within a living organism to biocompatible degradation products including the bioactive agent. Preferably, the released bioactive agent affects at least one of biological activity or chemical activity in the host organism. A biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is preferably derived from a diurea diol or a diester diol and is preferably biodegradable into biomolecule degradation products or into biomolecule degradation products and a biocompatible diol. Another biodegradable polyurethane composition includes hard segments and soft segments. Each of the hard segments is derived from a diurethane diol and is biodegradable into biomolecule degradation products.